TY - JOUR
T1 - BAHAMA
T2 - A Bayesian Hierarchical Model for the Detection of MedDRA®-Coded Adverse Events in Randomized Controlled Trials
AU - Revers, Alma
AU - Hof, Michel H.
AU - Zwinderman, Aeilko H.
N1 - Publisher Copyright: © 2022, The Author(s).
PY - 2022/9
Y1 - 2022/9
N2 - Introduction: Patients participating in randomized controlled trials (RCTs) are susceptible to a wide range of different adverse events (AE) during the RCT. MedDRA® is a hierarchical standardization terminology to structure the AEs reported in an RCT. The lowest level in the MedDRA hierarchy is a single medical event, and every higher level is the aggregation of the lower levels. Method: We propose a multi-stage Bayesian hierarchical Poisson model for estimating MedDRA-coded AE rate ratios (RRs). To deal with rare AEs, we introduce data aggregation at a higher level within the MedDRA structure and based on thresholds on incidence and MedDRA structure. Results: With simulations, we showed the effects of this data aggregation process and the method's performance. Furthermore, an application to a real example is provided and compared with other methods. Conclusion: We showed the benefit of using the full MedDRA structure and using aggregated data. The proposed model, as well as the pre-processing, is implemented in an R-package: BAHAMA.
AB - Introduction: Patients participating in randomized controlled trials (RCTs) are susceptible to a wide range of different adverse events (AE) during the RCT. MedDRA® is a hierarchical standardization terminology to structure the AEs reported in an RCT. The lowest level in the MedDRA hierarchy is a single medical event, and every higher level is the aggregation of the lower levels. Method: We propose a multi-stage Bayesian hierarchical Poisson model for estimating MedDRA-coded AE rate ratios (RRs). To deal with rare AEs, we introduce data aggregation at a higher level within the MedDRA structure and based on thresholds on incidence and MedDRA structure. Results: With simulations, we showed the effects of this data aggregation process and the method's performance. Furthermore, an application to a real example is provided and compared with other methods. Conclusion: We showed the benefit of using the full MedDRA structure and using aggregated data. The proposed model, as well as the pre-processing, is implemented in an R-package: BAHAMA.
UR - http://www.scopus.com/inward/record.url?scp=85134305260&partnerID=8YFLogxK
U2 - https://doi.org/10.1007/s40264-022-01208-w
DO - https://doi.org/10.1007/s40264-022-01208-w
M3 - Article
C2 - 35840802
SN - 0114-5916
VL - 45
SP - 961
EP - 970
JO - Drug safety
JF - Drug safety
IS - 9
ER -